Libros importados hasta 50% OFF + Envío Gratis a todo USA  Ver más

menu

0
  • argentina
  • chile
  • colombia
  • españa
  • méxico
  • perú
  • estados unidos
  • internacional
portada Pharmacokinetics in Drug Development: Problems and Challenges in Oncology, Volume 4 (in English)
Type
Physical Book
Publisher
Language
Inglés
Pages
330
Format
Paperback
Dimensions
23.4 x 15.6 x 1.8 cm
Weight
0.49 kg.
ISBN13
9783319818054

Pharmacokinetics in Drug Development: Problems and Challenges in Oncology, Volume 4 (in English)

Bonate, Peter L. ; Howard, Danny R. (Author) · Springer · Paperback

Pharmacokinetics in Drug Development: Problems and Challenges in Oncology, Volume 4 (in English) - Bonate, Peter L. ; Howard, Danny R.

Physical Book

$ 189.46

$ 199.99

You save: $ 10.53

5% discount
  • Condition: New
It will be shipped from our warehouse between Monday, July 08 and Tuesday, July 09.
You will receive it anywhere in United States between 1 and 3 business days after shipment.

Synopsis "Pharmacokinetics in Drug Development: Problems and Challenges in Oncology, Volume 4 (in English)"

In this volume, the specific challenges and problems facing the evaluation of new oncology agents are explored with regards to pharmacokinetic, pharmacodynamic modeling and clinical pharmacology development strategies. This book delivers, with an emphasis on the oncology therapeutic area, the goals set in the first three volumes: namely - to provide clinical pharmacologists practical insights for the application of pharmacology, pharmacokinetics and pharmacodynamics for new drug development strategies. Pharmacokinetic-pharmacodynamic concepts for tyrosine kinases, the evaluation of cardiac repolarization prolongation through QTc interval effects, efficacy- and safety-response analyses to support new drug approvals, clinical and preclinical tumor growth modeling, and flat- vs weight-based dose selection are showcased from an oncology clinical pharmacologist's point-of-view. Oncology development strategies are surveyed for new FDA-approvals to identify patterns in expectations at time of first approval. The special considerations necessary to address combination drug development, metronomics, biosimilars and breakthrough therapies are also presented.

Customers reviews

More customer reviews
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)

Frequently Asked Questions about the Book

All books in our catalog are Original.
The book is written in English.
The binding of this edition is Paperback.

Questions and Answers about the Book

Do you have a question about the book? Login to be able to add your own question.

Opinions about Bookdelivery

More customer reviews